About CELLPHIRE, INC.
Cellphire Therapeutics is a Maryland-based clinical-stage biotechnology company developing next-generation platelet-derived therapeutics to address unmet needs in acute bleeding and hemostasis. The company focuses on creating stabilized cellular therapies with extended shelf life and on-demand availability.
Development of platelet-derived therapeutics for acute hemorrhage in trauma, surgery, and critical careCreation of stabilized, freeze-dried platelet-derived hemostatic biologics (FPH Platform)Production of cryopreserved platelets (CPP) with extended shelf lifeManufacturing in a state-of-the-art cGMP facility meeting ISO 7 standardsClinical trials for products such as CLPH-511 and CLPH-211
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| Federal contract award | Department of Health and Human Services | $86.1M | |
| CRYOPRESERVED PLATELET (CPP) DEVELOPMENT FOR US FDA LICENSURE | Department of Defense | $60.0M | |
| Federal contract award | Department of Defense | $473K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to CELLPHIRE, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.